Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option.
- Author:
Andrew T GABRIELSON
1
;
Laith M ALZWERI
;
Wayne JG HELLSTROM
Author Information
- Publication Type:Review
- Keywords: Injections, intralesional; Microbial collagenase; Penile Induration; Therapeutics; Urologic diseases
- MeSH: Collagen; Collagenases*; Congenital Abnormalities; Fibrosis; Humans; Injections, Intralesional; Male; Microbial Collagenase*; Penile Induration*; Penis; Quality of Life; Treatment Outcome; Urologic Diseases
- From:The World Journal of Men's Health 2017;35(3):134-145
- CountryRepublic of Korea
- Language:English
- Abstract: Peyronie's disease (PD) is an inflammatory disorder characterized by an abnormal collagen deposition in the tunica albuginea of the penis, leading to fibrous and non-compliant plaques that can impede normal erection. Although pharmacological treatments are available, only intralesional injection therapy and surgical reconstruction have demonstrated tangible clinical efficacy in the management of this condition. Intralesional injection of collagenase clostridium histolyticum (CCH) has come to the forefront of minimally invasive treatment of PD. In this review, the authors provide an update on the safety, efficacy, and indications for CCH. The efficacy of CCH will be assessed on the basis of improvement in the severity of penile fibrosis, curvature, and pain. Numerous well-designed clinical trials and post-approval studies involving more than 1,500 patients have consistently demonstrated the efficacy and tolerability of CCH in the treatment of PD. CCH significantly decreases penile curvature and plaque consistency, as well as improves quality of life. Post-approval studies continue to demonstrate the efficacy of CCH despite broader inclusion criteria for treatment, such as the case with acute phase disease and atypical plaque deformities (i.e., ventral plaques, hourglass narrowing). CCH continues to be the gold standard for non-surgical management of stable phase PD, in the absence of strong evidence supporting oral therapy agents and ongoing evaluation of extracorporeal shockwave therapy. However, recent studies are beginning to provide precedent for the use of CCH in the management of acute phase and atypical PD.
